As of Feb 24
| +0.38 / +0.13%|
The 23 analysts offering 12-month price forecasts for Biogen have a median target of 310.00, with a high estimate of 366.60 and a low estimate of 265.00. The median estimate represents a +8.72% increase from the last price of 285.13.
The current consensus among 27 polled investment analysts is to Buy stock in Biogen. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.